ImmuCell (ICCC) Competitors

CARGO Therapeutics (NASDAQ:CRGX) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Is CRGX or ICCC more profitable?

CARGO Therapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -15.99%. ImmuCell's return on equity of -15.32% beat CARGO Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-38.16%	-33.94%
ImmuCell	-15.99%	-15.32%	-8.81%

Does the media prefer CRGX or ICCC?

In the previous week, ImmuCell had 5 more articles in the media than CARGO Therapeutics. MarketBeat recorded 7 mentions for ImmuCell and 2 mentions for CARGO Therapeutics. CARGO Therapeutics' average media sentiment score of 1.51 beat ImmuCell's score of 0.05 indicating that CARGO Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CARGO Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmuCell	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation and earnings, CRGX or ICCC?

ImmuCell has higher revenue and earnings than CARGO Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CARGO Therapeutics	N/A	N/A	-$98.15M	-$4.62	-0.89
ImmuCell	$26.49M	2.00	-$5.78M	-$0.07	-83.91

Do analysts recommend CRGX or ICCC?

CARGO Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 264.96%. Given CARGO Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CARGO Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
ImmuCell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more risk & volatility, CRGX or ICCC?

CARGO Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Does the MarketBeat Community believe in CRGX or ICCC?

ImmuCell received 107 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 66.67% of users gave CARGO Therapeutics an outperform vote.

Company	Underperform	Outperform
CARGO Therapeutics	Outperform Votes 14 66.67%	Underperform Votes 7 33.33%
ImmuCell	Outperform Votes 121 73.33%	Underperform Votes 44 26.67%

Do insiders & institutionals believe in CRGX or ICCC?

93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 2.9% of CARGO Therapeutics shares are owned by insiders. Comparatively, 6.6% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ImmuCell beats CARGO Therapeutics on 9 of the 16 factors compared between the two stocks.